Overview

Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the effect of repeated oral doses of eliglustat 150 mg twice daily (BID) on the pharmacokinetics (PK) of orally administered metoprolol 50 mg in healthy adults. The secondary objective is to assess the safety and tolerability of a single oral dose of metoprolol 50 mg when administered alone and in combination with repeated oral doses of eliglustat 150 mg BID in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Eliglustat
Metoprolol